| 肖望重,于慧,龙琼,等.单唾液酸四己糖神经节苷脂钠注射液不良事件及其救护措施[J].安徽医药,2022,26(3):633-636. |
| 单唾液酸四己糖神经节苷脂钠注射液不良事件及其救护措施 |
| Adverse drug events and treatment of monosialotetrahexosyl ganglioside sodium injection |
| |
| DOI：10.3969/j.issn.1009-6469.2022.03.050 |
| 中文关键词: 单唾液酸四己糖神经节苷脂钠 药品不良事件 救护措施 合理用药 |
| 英文关键词: Monosialotetrahexosyl ganglioside Sodium Adverse drug events Rescue measures Rational administration of drug |
| 基金项目:第四批湖南省老中医药专家学术经验继承项目(湘中医药函〔2020〕37号)；湖南省教育厅普通高等学校课程思政建设研究项目( HNKCSZ-2020-0260)；湖南省学位与研究生教育改革研究项目( 2020JGZD039)；湖南省 2020年一流本科课程精品在线开放课程( 374) |
|
| 摘要点击次数: 1219 |
| 全文下载次数: 411 |
| 中文摘要: |
| 目的探讨单唾液酸四己糖神经节苷脂钠注射液( GM1)致药品不良事件( ADE)的相关因素及其救护措施，为临床合理用药提供依据。方法对湖南中医药大学第一附属医院 2019年 1月至 2020年 12月发生的 12例 GM1致 ADE报告进行回顾性分析。结果 GM1致 ADE多在用药后 5 min~12 d内，主要表现为寒战、发热等全身性损害 7例次；其余为皮肤损害 3例次、呼吸系统与心血管系统损害各 2例次、神经系统损害 1例次，以及出现说明书未提及的视物模糊 1例次，经过停药并对症处理后上述症状均明显缓解。结论临床在使用 GM1前应详细询问病人过敏史，优先选择 5%葡萄糖注射液做溶媒，缓慢滴注；在用药过程中应加强 ADE监测，一旦发生立即停药，并考虑使用地塞米松注射剂 5 mg或 10 mg静滴等对症治疗。 |
| 英文摘要: |
| Objective To investigate the related factors and treatment measures of adverse drug events (ADE) related to monosialotetrahexosyl ganglioside sodium injection(GM1), and to provide evidence for rational drug use in clinical practice.Methods A retrospective analysis was made of 12 cases with ADE caused by intravenous infusion of GM1 reported in The First Affiliated Hospital ofHunan University of Chinese Medicine from January 2019 to December 2020.Results The ADE caused by GM1 occurred mostly within 5 min to 12 days after medication. The main manifestations were shivering, fever and other systemic damage in 7 cases. The restwere skin damage in 3 cases, respiratory system and cardiovascular system damage in respective 2 cases, nervous system damage in 1case, and blurred vision in 1 case which was not mentioned in drug instruction. The above symptoms were obviously relieved after withdrawal of medication and symptomatic treatment.Conclusions Before using the injection clinically, patients should be asked abouttheir allergy history in detail, and 5% glucose injection should be selected preferentially as solvent with slow dripping. In the process ofmedication, the monitoring of ADE should be strengthened. Once adverse reactions are found, the drug should be withdrawn immediately, and symptomatic treatment such as 5 mg/10 mg intravenous drip of dexamethasone injection could be considered. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
